Shoker Investment Counsel Inc. Buys 576 Shares of Johnson & Johnson (NYSE:JNJ)

Shoker Investment Counsel Inc. increased its stake in Johnson & Johnson (NYSE:JNJ) by 3.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,147 shares of the company’s stock after buying an additional 576 shares during the quarter. Johnson & Johnson comprises approximately 1.1% of Shoker Investment Counsel Inc.’s holdings, making the stock its 29th largest holding. Shoker Investment Counsel Inc.’s holdings in Johnson & Johnson were worth $3,176,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Geode Capital Management LLC lifted its position in Johnson & Johnson by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company’s stock worth $8,321,881,000 after buying an additional 1,561,036 shares during the last quarter. Northern Trust Corp increased its stake in Johnson & Johnson by 12.3% in the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company’s stock worth $4,456,201,000 after purchasing an additional 3,363,235 shares during the period. Wellington Management Group LLP increased its stake in Johnson & Johnson by 1.8% in the fourth quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company’s stock worth $3,522,447,000 after purchasing an additional 431,205 shares during the period. Bank of New York Mellon Corp increased its stake in Johnson & Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock worth $3,844,580,000 after purchasing an additional 4,842,582 shares during the period. Finally, Invesco Ltd. increased its stake in Johnson & Johnson by 6.5% in the fourth quarter. Invesco Ltd. now owns 19,126,079 shares of the company’s stock worth $2,766,014,000 after purchasing an additional 1,171,975 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

JNJ opened at $168.29 on Monday. The business’s 50-day moving average is $156.08 and its two-hundred day moving average is $155.97. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a market capitalization of $404.92 billion, a PE ratio of 18.00, a price-to-earnings-growth ratio of 2.14 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the previous year, the firm earned $2.82 earnings per share. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.09%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on JNJ shares. Royal Bank Of Canada increased their target price on Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research note on Thursday, July 17th. Bank of America increased their target price on Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Thursday, July 17th. Wall Street Zen lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 18th. Raymond James Financial reduced their target price on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research note on Monday, April 14th. Finally, Morgan Stanley increased their target price on Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Nine analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $174.50.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.